Foresite Capital Management II, LLC - AIMMUNE THERAPEUTICS INC ownership

Quarter-by-quarter ownership
Foresite Capital Management II, LLC ownership history of AIMMUNE THERAPEUTICS INC
ValueSharesWeighting
Q3 2019$54,559,000
-3.9%
2,605,499
-4.4%
11.53%
-63.9%
Q2 2019$56,767,000
-6.8%
2,726,5680.0%31.92%
+16.0%
Q1 2019$60,939,000
-14.2%
2,726,568
-8.2%
27.51%
-26.9%
Q4 2018$71,010,000
-21.1%
2,968,649
-10.1%
37.63%
+12.9%
Q3 2018$90,046,000
-0.2%
3,300,797
-1.7%
33.32%
+4.8%
Q2 2018$90,263,000
-14.6%
3,356,749
+1.1%
31.80%
-9.5%
Q1 2018$105,674,000
-9.9%
3,319,945
+7.1%
35.15%
-14.2%
Q4 2017$117,248,000
+23.8%
3,100,146
-18.9%
40.96%
+6.7%
Q3 2017$94,709,000
+15.4%
3,820,462
-4.3%
38.39%
+2.1%
Q2 2017$82,086,000
-5.4%
3,992,5170.0%37.61%
+1.1%
Q1 2017$86,757,000
+10.6%
3,992,517
+4.1%
37.22%
-5.5%
Q4 2016$78,443,000
+31.8%
3,835,830
-3.3%
39.37%
+38.5%
Q3 2016$59,519,000
+38.6%
3,967,9000.0%28.42%
-3.2%
Q2 2016$42,933,000
-22.5%
3,967,900
-2.9%
29.35%
+8.2%
Q1 2016$55,432,000
-26.5%
4,087,9000.0%27.13%
+7.3%
Q4 2015$75,422,000
-27.1%
4,087,9000.0%25.29%
-19.5%
Q3 2015$103,506,0004,087,90031.43%
Other shareholders
AIMMUNE THERAPEUTICS INC shareholders Q2 2024
NameSharesValueWeighting ↓
Aisling Capital LLC 1,240,000$25,966,00057.34%
Foresite Capital Management II, LLC 2,605,499$54,559,00011.53%
Foresite Capital Management III, LLC 611,893$12,813,0004.89%
Palo Alto Investors LP 3,471,740$72,698,0004.84%
SANDERS MORRIS HARRIS LLC 486,906$10,196,0002.47%
Eventide Asset Management 3,084,000$64,579,0002.13%
Sofinnova Investments, Inc. 346,770$7,261,0000.66%
EMERALD ADVISERS, LLC 610,511$12,784,0000.60%
RICE HALL JAMES & ASSOCIATES, LLC 752,358$15,754,0000.56%
EMERALD MUTUAL FUND ADVISERS TRUST 587,464$12,301,0000.54%
View complete list of AIMMUNE THERAPEUTICS INC shareholders